FDA Approves Alimta As Lung-Cancer Maintenance Therapy - WSJ.com
Links shared publicly online about this topic.
- 1,916total visits
FDA Approves Alimta As Lung-Cancer Maintenance Therapy - WSJ.com
View full resource at online.wsj.com
Tags: Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Medication, Lung, Disease and Condition, Drug, FDA, Alimta, Doctor
Most Recently Shared on July 7, 2009 at 12:53 am By:
Chemotherapy Drug Gains New Approval http://tinyurl.com/mvhdlp
EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC
news-medical.net — “Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer” View full resource at news-medical.net
Most Recently Shared on October 29, 2011 at 5:56 am By:
Lung Cancer News: EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC: Eli Lilly and Compan... http://t.co/xBsLdjbe
FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer | Business Wire
businesswire.com — “MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. “We are delighted that lung cancer patients and their physicians will have the option of beginning Ta” View full resource at businesswire.com
Most Recently Shared on April 19, 2010 at 3:36 pm By:
Naoto T. Ueno Oncologist, Physician, Doctor, and Internist
RT @cancer_drugs Business Week: FDA Approves Tarceva as Maintenance Therapy 4 Advanced Non-Small Cell Lung #cancer http://bit.ly/9ghaDc
Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) - MPR
empr.com — “Genentech announced that the FDA has approved Tarceva (erlotinib tablets) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at empr.com
Most Recently Shared on April 19, 2010 at 3:17 pm By:
MPR News: Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC): Genentech annou... http://bit.ly/aL6GEI
Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) - ONA
oncologynurseadvisor.com — “Genentech announced that the FDA has approved Tarceva (erlotinib tablets) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at oncologynurseadvisor.com
Most Recently Shared on April 19, 2010 at 2:54 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) http://goo.gl/fb/8XCZx
FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
drugs.com — “Tarceva (erlotinib) is used to treat non-small cell lung cancer and pancreatic cancer. Includes Tarceva side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on April 18, 2010 at 10:38 pm By:
FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer - http://bit.ly/cVy4LL
Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC
news-medical.net — “Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at news-medical.net
Most Recently Shared on April 17, 2010 at 6:50 am By:
Stroke News: Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC: Genentech, Inc... http://twurl.nl/kuh4rr
Eli Lilly and Company - ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
newsroom.lilly.com — “Eli Lilly and Company - ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer” View full resource at newsroom.lilly.com
Most Recently Shared on July 10, 2009 at 5:45 pm By:
eyeonfda Pharma and Health Lawyer
ALIMTA(R) (pemetrexed for injection) 1st Approval in EUas Maintenance Therapy for Adv Nonsquamous NSC Lung Cancer http://bit.ly/rwSmS
Alimta Approved as Maintenance Therapy for Advanced Lung Cancer - iVillage Your Total Health
yourtotalhealth.ivillage.com — “The drug Alimta (pemetrexed) has been approved by the U.S. Food and Drug Administration to prevent progression of certain types of advanced or metastatic (spreading) lung cancer, the agency said Monday.” View full resource at yourtotalhealth.ivillage.com
Most Recently Shared on July 6, 2009 at 6:48 pm By:
Alimta Approved as Maintenance Thera... http://bit.ly/ezfi5
Alimta approved for nonsquamous non-small cell lung cancer (NSCLC) maintenance therapy - MPR
empr.com — “The FDA has approved Alimta (pemetrexed injection, from Eli Lilly) as maintenance therapy for patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at empr.com
Most Recently Shared on July 6, 2009 at 3:50 pm By:
MPR News: Alimta approved for nonsquamous non-small cell lung cancer (NSCLC) maintenance therapy: The F.. http://tinyurl.com/mvpd5u
Eli Lilly and Company - Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
newsroom.lilly.com — “Eli Lilly and Company - Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)” View full resource at newsroom.lilly.com
Most Recently Shared on July 6, 2009 at 2:56 pm By:
eyeonfda Pharma and Health Lawyer
ALIMTA First Chemotherapy Approved As Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer - http://bit.ly/bN3Lz
Advertisement
